114 related articles for article (PubMed ID: 1334054)
1. Novobiocin-induced accumulation of etoposide (VP-16) in WEHI-3B D+ leukemia cells.
Lorico A; Rappa G; Sartorelli AC
Int J Cancer; 1992 Dec; 52(6):903-9. PubMed ID: 1334054
[TBL] [Abstract][Full Text] [Related]
2. Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene.
Lorico A; Rappa G; Srimatkandada S; Catapano CV; Fernandes DJ; Germino JF; Sartorelli AC
Cancer Res; 1995 Oct; 55(19):4352-60. PubMed ID: 7671247
[TBL] [Abstract][Full Text] [Related]
3. Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26).
Rappa G; Lorico A; Sartorelli AC
Int J Cancer; 1992 Jul; 51(5):780-7. PubMed ID: 1377186
[TBL] [Abstract][Full Text] [Related]
4. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1992 May; 52(10):2782-90. PubMed ID: 1316227
[TBL] [Abstract][Full Text] [Related]
5. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1993 Nov; 53(22):5487-93. PubMed ID: 8106148
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity studies of novobiocin analogs as modulators of the cytotoxicity of etoposide (VP-16).
Rappa G; Shyam K; Lorico A; Fodstad O; Sartorelli AC
Oncol Res; 2000; 12(3):113-9. PubMed ID: 11216669
[TBL] [Abstract][Full Text] [Related]
7. Induction of the differentiation of WEHI-3B D+ monomyelocytic leukemia cells by inhibitors of topoisomerase II.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1990 Oct; 50(20):6723-30. PubMed ID: 2170008
[TBL] [Abstract][Full Text] [Related]
8. Novobiocin-induced VP-16 accumulation and MRP expression in human leukemia and ovarian carcinoma cells.
Rappa G; Murren JR; Johnson LM; Lorico A; Sartorelli AC
Anticancer Drug Des; 2000 Apr; 15(2):127-34. PubMed ID: 10901300
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.
Long BH; Wang L; Lorico A; Wang RC; Brattain MG; Casazza AM
Cancer Res; 1991 Oct; 51(19):5275-83. PubMed ID: 1717144
[TBL] [Abstract][Full Text] [Related]
10. Verapamil-induced augmentation of etoposide accumulation in L1210 cells in vitro.
Yalowich JC; Ross WE
Cancer Res; 1985 Apr; 45(4):1651-6. PubMed ID: 3978633
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase-II-mediated lesions in nascent DNA: comparison of the effects of epipodophyllotoxin derivatives, VM-26 and VP-16, and 9-anilinoacridine derivatives, m-AMSA and o-AMSA.
Woynarowski JM; Sigmund RD; Beerman TA
Biochim Biophys Acta; 1988 May; 950(1):21-9. PubMed ID: 2833925
[TBL] [Abstract][Full Text] [Related]
12. Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxins in simian virus 40-infected monkey cells.
Yang L; Rowe TC; Liu LF
Cancer Res; 1985 Nov; 45(11 Pt 2):5872-6. PubMed ID: 2996763
[TBL] [Abstract][Full Text] [Related]
13. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
[TBL] [Abstract][Full Text] [Related]
14. Cross-resistance of novobiocin-resistant BHK cell line to topoisomerase II inhibitors.
Ishida R; Nishizawa M; Nishimoto T; Takahashi T
Somat Cell Mol Genet; 1988 Sep; 14(5):489-97. PubMed ID: 2845588
[TBL] [Abstract][Full Text] [Related]
15. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells.
Takano H; Kohno K; Ono M; Uchida Y; Kuwano M
Cancer Res; 1991 Aug; 51(15):3951-7. PubMed ID: 1649696
[TBL] [Abstract][Full Text] [Related]
16. Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs.
Epstein RJ; Smith PJ
Cancer Res; 1988 Jan; 48(2):297-303. PubMed ID: 2825970
[TBL] [Abstract][Full Text] [Related]
17. Antifolates can potentiate topoisomerase II inhibitors in vitro and in vivo.
Holden SA; Teicher BA; Robinson MF; Northey D; Rosowsky A
Cancer Chemother Pharmacol; 1995; 36(2):165-71. PubMed ID: 7767954
[TBL] [Abstract][Full Text] [Related]
18. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.
Ritke MK; Allan WP; Fattman C; Gunduz NN; Yalowich JC
Mol Pharmacol; 1994 Jul; 46(1):58-66. PubMed ID: 8058057
[TBL] [Abstract][Full Text] [Related]
19. Altered DNA-cleavage activity of topoisomerase II from WEHI-3B leukemia cells with specific resistance to ciprofloxacin.
Pessina A; Raimondi A; Croera C; Acchini M; Mineo E; Foti P; Neri MG
Anticancer Drugs; 2001 Jun; 12(5):441-51. PubMed ID: 11395572
[TBL] [Abstract][Full Text] [Related]
20. The mechanism of epipodophyllotoxin-induced thymocyte apoptosis: possible role of a novel Ca(2+)-independent protein kinase.
Ye X; Georgoff I; Fleisher S; Coffman FD; Cohen S; Fresa KL
Cell Immunol; 1993 Oct; 151(2):320-35. PubMed ID: 8402939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
